智通财经APP获悉，艾美疫苗(06660)现涨超13%，截至发稿，涨12.78%，报3.97港元，成交额1851.32万港元。
消息面上，艾美疫苗发布公告称，公司2024年录得收入12.5亿至13亿之间，同比增加5%至9%；净亏损介乎人民币2.5亿元至2.9亿元之间，减亏幅度85%至87%。亏损大幅度减少主要因为大额资产减值损失金额减少，以及由乙肝疫苗带动的收入增加。
国证国际认为，艾美未来三年预计每年将有1-2款产品上市，若在研产品陆续成功获批上市，同时产品出海进展顺利，有望为公司带来新的财报增长点并打开市场天花板。复星国际证券认为，2024-2027年艾美收入复合年增长率将达到47%，预计2025年实现盈亏平衡，2027年净利润有望突破15.2亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.